Screener / SEC EDGAR /CIK 0001699031 /10-K filed Mar 12, 2026, compared with Mar 5, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

GRAIL, Inc. GRAL

Compare with peers Embed
Planned sales, announced before they happen

3 trading plans running, 20 Form 144 notices for $38.1M

10-Q, 10-K and Form 144
Plans running now 3 Mr. Aaron Freidin, Dr. Joshua Ofman, Aaron Freidin
Plans adopted 6 reported since Aug 13, 2024 Form 144 notices 20 $38.1M the sellers expected to sell

What GRAL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 13, 2025 to Mar 19, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Mr. Aaron Freidin
Chief Financial Officer
Adopted 10b5-1 plan Dec 11, 2025 10-K Mar 12, 2026
What the company wrote
On December 11, 2025, Mr. Aaron Freidin, Chief Financial Officer of the Company, modified a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (as modified, the “2026 Freidin Trading Arrangement”). The 2026 Freidin Trading Arrangement modifies the 2025 Freidin Trading Arrangement, as defined in our Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and provides for the sale of up to 21,000 shares of common stock, subject to price limitations, until March 19, 2027.
Dr. Joshua Ofman
President
Adopted 10b5-1 plan Dec 2, 2025 10-K Mar 12, 2026
What the company wrote
On December 2, 2025, Dr. Joshua Ofman, President of the Company, modified a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (as modified, the “2026 Ofman Trading Arrangement”). The 2026 Ofman Trading Arrangement modifies the 2025 Ofman Trading Arrangement, as defined in our Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and provides for the sale of up to 86,452 shares of common stock, subject to price limitations, until February 20, 2027.
Sarah Krevans
member of the Board of Directors
Adopted 10b5-1 plan May 22, 2025 10-Q Aug 13, 2025
What the company wrote
On May 22, 2025, Sarah Krevans, a member of the Board of Directors, terminated a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “2025 Krevans Trading Arrangement”). The 2025 Krevans Trading Arrangement was entered into on March 13, 2025 and provided for the sale of up to 6,210 shares of common stock, subject to price limitations. The plan had an end date of June 19, 2026.
Aaron Freidin
Chief Financial Officer,
Adopted 10b5-1 plan Mar 13, 2025 10-Q May 14, 2025
What the company wrote
March 13, 2025, Aaron Freidin, our Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 64,000 shares of common stock until March 14, 2027.
Joshua Ofman
President
Adopted 10b5-1 plan Mar 13, 2025 10-Q May 14, 2025
What the company wrote
On March 13, 2025, Joshua Ofman, our President, entered into a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 100% of the net shares of common stock received by Mr. Ofman from his RSU award covering 92,269 shares of common stock until May 29, 2026.
Sarah Krevans
member of the Board of Directors
Adopted 10b5-1 plan Mar 13, 2025 10-Q May 14, 2025
What the company wrote
On March 13, 2025, Sarah Krevans, a member of the Board of Directors, entered into a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 6,210 shares of common stock until June 19, 2026.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 10 filings checked since Aug 13, 2024.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 15, 2026 JOSHUA OFMAN
Director, Officer
5,000 $698K
Oct 5, 2026 Andrew Partridge
Officer
7,873 $1.2M
Oct 5, 2026 Aaron Freidin
Officer
23,619 $3.5M
Sep 21, 2026 JOSHUA OFMAN
Director, Officer
71,452 $5.8M
Aug 27, 2026 JOSHUA OFMAN
Director, Officer
10,000 $796K
Aug 27, 2026 AARON FREIDIN
Officer
12,000 $955K
Jun 3, 2026 Andrew Partridge
Officer
1,705 $104K
Apr 6, 2026 Aaron Freidin
Officer
49,414 $2.6M
Apr 6, 2026 Joshua Ofman
Officer, Director
66,522 $3.4M
Apr 6, 2026 Robert Ragusa
Officer, Director
133,230 $6.9M
Mar 5, 2026 Aaron Freidin
Officer
3,471 $180K
Mar 5, 2026 Robert Ragusa
Officer, Director
9,285 $481K
Mar 5, 2026 Joshua J. Ofman
Officer
3,999 $207K
Mar 2, 2026 Joshua J. Ofman
Officer
18,423 $981K
Mar 2, 2026 Aaron Freidin
Officer
10,374 $552K
Mar 2, 2026 Robert Ragusa
Officer, Director
40,641 $2.2M
Dec 3, 2025 AARON FREIDIN
Officer
25,000 $2.5M
Dec 3, 2025 JOSHUA J OFMAN
Officer
13,000 $1.3M
Dec 3, 2025 ROBERT P RAGUSA
Officer, Director
40,000 $3.8M
Nov 14, 2025 Aaron Freidin
Officer
1,940 $154K
Show the other 12 notices

From the Form 144 XML filed with the SEC, since Nov 14, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.